Login to Your Account



China cuts Astrazeneca, Glaxosmithkline and Betta drug prices

By Cornelia Zou
Staff Writer

Monday, May 23, 2016

HONG KONG – As part of its efforts to continue reforming China's medical system, the National Health and Family Planning Commission (NHFPC) slashed the price of three top-selling drugs of both foreign and domestic companies by more than half.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription